# DaVita Inc. – Consensus ‘hold’ rating and -4.2% Downside Potential

- Link: https://www.directorstalkinterviews.com/davita-inc.consensus-hold-rating-and-4.2-downside-potential/4121174948
- Published: 2024-10-23T15:08:13+01:00
- Author: Charlotte Edwards

**DaVita Inc.** with ticker code (DVA) have now 8 confirmed analysts covering the
stock with the consensus suggesting a rating of ‘hold’. The range between the high
target price and low target price is between $175.00 and $137.12 calculating the
mean target price we have $154.76. Given that the stocks previous close was at $
161.54 this indicates there is a potential downside of -4.2%. It’s also worth noting
that there is a 50 day moving average of $157.35 and the 200 day MA is $138.00. 
The company has a market capitalization of 13.69B. The price for the stock stands
currently at: $163.16 USD

 The potential market cap would be $13,114,577,228 based on the market consensus.

The company has a dividend yield of 3.8%. Other points of data to note are a P/E
ratio of 17.36, revenue per share of $140.59 and a 6.8% return on assets.

DaVita Inc. is a healthcare provider. The Company provides kidney care services 
in the United States. The Company’s operations are comprised of its U.S. dialysis
and related lab services business (its U.S. dialysis business), its U.S. integrated
kidney care business, its U.S. other ancillary services and its international operations(
its ancillary services). The U.S. dialysis and related lab services (U.S. dialysis)
business treats patients with chronic kidney failure, and end-stage kidney disease(
ESKD). Its services include outpatient hemodialysis services, hospital inpatient
hemodialysis services, and home-based dialysis services. The ancillary services 
consist of integrated kidney care services, physician services, clinical research
programs, and transplant software business, as well as international operations.
The Company operates approximately 2,724 outpatient dialysis centers in the United
States.

Share on: